About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

CNS Lymphoma >  ASCO 2012 - CNS Lymphoma

Last update: 06/03/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

  1. Central nervous system involvement in T-cell lymphomas: A single center experience. | 2012 ASCO Annual Meeting Abstracts

     
  2. Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Children's Oncology Group. | 2012 ASCO Annual Meeting Abstracts

     
  3. CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. | 2012 ASCO Annual Meeting Abstracts

     
  4. Recurrent genetic alterations in primary central nervous system lymphoma of immunocompetent patients. | 2012 ASCO Annual Meeting Abstracts

     
  5. Primary central nervous system lymphoma: The Cleveland Clinic experience. | 2012 ASCO Annual Meeting Abstracts

     
  6. Primary CNS lymphoma: A review of clinicopathologic characteristics, therapy, and outcomes of 54 patients with primary CNS DLBCL. | 2012 ASCO Annual Meeting Abstracts

     
  7. Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial. | 2012 ASCO Annual Meeting Abstracts

     
  8. The natural history of intravascular lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  9. High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  10. Central nervous system lymphoma: Prognostic factors. | 2012 ASCO Annual Meeting Abstracts

     
  11. Utility of iron oxide nanoparticles in the radiographic diagnosis of CNS lymphoma and inflammatory diseases. | 2012 ASCO Annual Meeting Abstracts

     
  12. Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. | 2012 ASCO Annual Meeting Abstracts

     
  13. Relationship of cognitive function, quality of life (QOL), and neuroimaging in primary CNS lymphoma (PCNSL) survivors. | 2012 ASCO Annual Meeting Abstracts

     
  14. The natural history of intravascular lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  15. Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL). | 2012 ASCO Annual Meeting Abstracts

     

 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.